Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review
Grant SJ, Grimshaw AA, Silberstein J, Murdaugh D, Wildes TM, Rosko AE, Giri S. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. Transplantation And Cellular Therapy 2022, 28: 294-302. PMID: 35288347, PMCID: PMC9197870, DOI: 10.1016/j.jtct.2022.03.006.Peer-Reviewed Original ResearchConceptsImmune effector cell-associated neurotoxicity syndromeCAR T-cell therapyT-cell therapyLong-term outcomesHematologic malignanciesCell therapyClinical presentationLymphocytic leukemiaCAR-T cell therapy recipientsChimeric antigen receptor T-cell therapyJoanna Briggs Institute critical appraisal toolsDiffuse large B-cell lymphomaCAR T-cell productsLarge B-cell lymphomaCytokine release syndromeRefractory hematologic malignanciesLong-term sequelaeSubset of patientsC-reactive proteinCommon hematologic malignancyLife-threatening conditionNon-Hodgkin lymphomaCross-trial comparisonsAcute lymphocytic leukemiaChronic lymphocytic leukemia